Human Monoclonal Antibody HCV1 Effectively Prevents and Treats HCV Infection in Chimpanzees

English version České info

Hepatitis C virus (HCV) infection is a leading cause of liver transplantation and there is an urgent need to develop therapies to reduce rates of HCV infection of transplanted livers. Approved therapeutics for HCV are poorly tolerated and are of limited efficacy in this patient population. Human monoclonal antibody HCV1 recognizes a highly-conserved linear epitope of the HCV E2 envelope glycoprotein (amino acids 412–423) and neutralizes a broad range of HCV genotypes. In a chimpanzee model, a single dose of 250 mg/kg HCV1 delivered 30 minutes prior to infusion with genotype 1a H77 HCV provided complete protection from HCV infection, whereas a dose of 50 mg/kg HCV1 did not protect. In addition, an acutely-infected chimpanzee given 250 mg/kg HCV1 42 days following exposure to virus had a rapid reduction in viral load to below the limit of detection before rebounding 14 days later. The emergent virus displayed an E2 mutation (N415K/D) conferring resistance to HCV1 neutralization. Finally, three chronically HCV-infected chimpanzees were treated with a single dose of 40 mg/kg HCV1 and viral load was reduced to below the limit of detection for 21 days in one chimpanzee with rebounding virus displaying a resistance mutation (N417S). The other two chimpanzees had 0.5–1.0 log₁₀ reductions in viral load without evidence of viral resistance to HCV1. In vitro testing using HCV pseudovirus (HCVpp) demonstrated that the sera from the poorly-responding chimpanzees inhibited the ability of HCV1 to neutralize HCVpp. Measurement of antibody responses in the chronically-infected chimpanzees implicated endogenous antibody to E2 and interference with HCV1 neutralization although other factors may also be responsible. These data suggest that human monoclonal antibody HCV1 may be an effective therapeutic for the prevention of graft infection in HCV-infected patients undergoing liver transplantation.

Vyšlo v časopise: Human Monoclonal Antibody HCV1 Effectively Prevents and Treats HCV Infection in Chimpanzees. PLoS Pathog 8(8): e32767. doi:10.1371/journal.ppat.1002895
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1002895

Souhrn

Zdroje

1. LavanchyD (2009) The global burden of hepatitis C. Liver Int 29: 74–81.

2. ShepardCW, FinelliL, AlterMJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5: 558–567.

3. AlterHJ, SeeffLB (2000) Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 20: 17–35.

4. MakrisM, PrestonFE, RosendaalFR, UnderwoodJC, RiceKM, et al. (1996) The natural history of chronic hepatitis C in haemophiliacs. Br J Haematol 94: 746–752.

5. FornsX, Garcia-RetortilloM, SerranoT, FeliuA, SuarezF, et al. (2003) Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 39: 389–396.

6. EversonGT, TrotterJ, FormanL, KugelmasM, HalprinA, et al. (2005) Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 42: 255–262.

7. ChalasaniN, ManzarbeitiaC, FerenciP, VogelW, FontanaRJ, et al. (2005) Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 41: 289–298.

8. BzowejN, NelsonDR, TerraultNA, EversonGT, TengLL, et al. (2011) PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl 17: 528–538.

9. KnodellRG, ConradME, GinsbergAL, BellCJ (1976) Efficacy of prophylactic gamma-globulin in preventing non-A, non-B post-transfusion hepatitis. Lancet 1: 557–561.

10. Sanchez-QuijanoA, PinedaJA, LissenE, LealM, Diaz-TorresMA, et al. (1988) Prevention of post-transfusion non-A, non-B hepatitis by non-specific immunoglobulin in heart surgery patients. Lancet 1: 1245–1249.

11. PiazzaM, SaglioccaL, TosoneG, GuadagninoV, StaziMA, et al. (1998) Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial. Arch Intern Med 157: 1537–1544.

12. PestkaJM, ZeiselMB, BlaserE, SchurmannP, BartoschB, et al. (2007) Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A 104: 6025–6030 Epub 2007 Mar 6028.

13. DavisGL (2006) Hepatitis C immune globulin to prevent HCV recurrence after liver transplantation: chasing windmills? Liver Transpl 12: 1317–1319.

14. SchianoTD, CharltonM, YounossiZ, GalunE, PruettT, et al. (2006) Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl 12: 1381–1389.

15. SamuelD, MullerR, AlexanderG, FassatiL, DucotB, et al. (1993) Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 329: 1842–1847.

16. TodoS, DemetrisAJ, Van ThielD, TepermanL, FungJJ, et al. (1991) Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 13: 619–626.

17. FerayC, GigouM, SamuelD, DucotB, MaisonneuveP, et al. (1998) Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann Intern Med 128: 810–816.

18. Op De BeeckA, CocquerelL, DubuissonJ (2001) Biogenesis of hepatitis C virus envelope glycoproteins. J Gen Virol 82: 2589–2595.

19. BartoschB, DubuissonJ, CossetFL (2003) Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 197: 633–642.

20. HsuM, ZhangJ, FlintM, LogvinoffC, Cheng-MayerC, et al. (2003) Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A 100: 7271–7276 Epub 2003 May 7221.

21. PileriP, UematsuY, CampagnoliS, GalliG, FalugiF, et al. (1998) Binding of hepatitis C virus to CD81. Science 282: 938–941.

22. EvansMJ, von HahnT, TscherneDM, SyderAJ, PanisM, et al. (2007) Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446: 801–805.

23. PlossA, EvansMJ, GaysinskayaVA, PanisM, YouH, et al. (2009) Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457: 882–886.

24. ScarselliE, AnsuiniH, CerinoR, RoccaseccaRM, AcaliS, et al. (2002) The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. Embo J 21: 5017–5025.

25. von HahnT, RiceCM (2008) Hepatitis C virus entry. J Biol Chem 283: 3689–3693 Epub 2007 Sep 3619.

26. BroeringTJ, GarrityKA, BoatrightNK, SloanSE, SandorF, et al. (2009) Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. J Virol 83: 12473–12482 Epub 12009 Sep 12416.

27. Blair B, Babcock G, Szabo G, Finberg R, Cheslock P, et al.. (2009) Human Monoclonal Antibodies Directed Against the E2 Glycoprotein of Hepatitis C Virus (HCV) Prevents Infection in Chimpanzees [Abstract 1048]. In: Proceedings of the 44th Annual Meeting of the European Association for the Study of the Liver; 22–26 April 2009; Copenhagen, Denmark. EASL 2009. Available: http://www.kenes.com/easl2009/posters/Abstract48.htm.

28. TarrAW, OwsiankaAM, JayarajD, BrownRJ, HicklingTP, et al. (2007) Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33. J Gen Virol 88: 2991–3001.

29. BukhJ, MeulemanP, TellierR, EngleRE, FeinstoneSM, et al. (2010) Challenge pools of hepatitis C virus genotypes 1–6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models. J Infect Dis 201: 1381–1389.

30. KrawczynskiK, AlterMJ, TankersleyDL, BeachM, RobertsonBH, et al. (1996) Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J Infect Dis 173: 822–828.

31. FarciP, AlterHJ, WongDC, MillerRH, GovindarajanS, et al. (1994) Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A 91: 7792–7796.

32. FarciP, ShimodaA, WongD, CabezonT, De GioannisD, et al. (1996) Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A 93: 15394–15399.

33. Sanchez-FueyoA, RestrepoJC, QuintoL, BrugueraM, GrandeL, et al. (2002) Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation 73: 56–63.

34. FormanLM, LewisJD, BerlinJA, FeldmanHI, LuceyMR (2002) The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 122: 889–896.

35. BerenguerM, PrietoM, San JuanF, RayonJM, MartinezF, et al. (2002) Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 36: 202–210.

36. FerayC, CaccamoL, AlexanderGJ, DucotB, GugenheimJ, et al. (1999) European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 117: 619–625.

37. GaneE (2003) The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 9: S28–34.

38. PrietoM, BerenguerM, RayonJM, CordobaJ, ArguelloL, et al. (1999) High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 29: 250–256.

39. VelidedeogluE, MangeKC, FrankA, AbtP, DesaiNM, et al. (2004) Factors differentially correlated with the outcome of liver transplantation in hcv+ and HCV- recipients. Transplantation 77: 1834–1842.

40. GaneEJ, PortmannBC, NaoumovNV, SmithHM, UnderhillJA, et al. (1996) Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 334: 815–820.

41. Gallegos-OrozcoJF, YosephyA, NobleB, AqelBA, ByrneTJ, et al. (2009) Natural history of post-liver transplantation hepatitis C: A review of factors that may influence its course. Liver Transpl 15: 1872–1881.

42. BerenguerM (2008) Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 49: 274–287.

43. ZhangP, WuCG, MihalikK, Virata-TheimerML, YuMY, et al. (2007) Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc Natl Acad Sci U S A 104: 8449–8454.

44. ZhangP, ZhongL, StrubleEB, WatanabeH, KachkoA, et al. (2009) Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc Natl Acad Sci U S A 106: 7537–7541.

45. TarrAW, UrbanowiczRA, JayarajD, BrownRJ, McKeatingJA, et al. (2012) Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization. J Virol 86: 2739–2749.

46. VoissetC, CallensN, BlanchardE, Op De BeeckA, DubuissonJ, et al. (2005) High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J Biol Chem 280: 7793–7799.

47. DreuxM, PietschmannT, GranierC, VoissetC, Ricard-BlumS, et al. (2006) High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J Biol Chem 281: 18285–18295.

48. LindenbachBD, EvansMJ, SyderAJ, WolkB, TellinghuisenTL, et al. (2005) Complete replication of hepatitis C virus in cell culture. Science 309: 623–626.

49. WakitaT, PietschmannT, KatoT, DateT, MiyamotoM, et al. (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11: 791–796.

50. ZhongJ, GastaminzaP, ChengG, KapadiaS, KatoT, et al. (2005) Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 102: 9294–9299.

51. LindenbachBD, MeulemanP, PlossA, VanwolleghemT, SyderAJ, et al. (2006) Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A 103: 3805–3809.

52. KeckZY, XiaJ, CaiZ, LiTK, OwsiankaAM, et al. (2007) Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions. J Virol 81: 1043–1047.

53. HelleF, VieyresG, ElkriefL, PopescuCI, WychowskiC, et al. (2010) Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions. J Virol 84: 11905–11915.

54. LiuS, McCormickKD, ZhaoW, ZhaoT, FanD, et al. (2012) Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding. Hepatology 2012: 25665.

55. KolykhalovAA, AgapovEV, BlightKJ, MihalikK, FeinstoneSM, et al. (1997) Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 277: 570–574.